Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSMA PET Imaging of Recurrent Prostate Cancer
NCT03204123Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2017
- Primary completion
- Jun 2027
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label trial of gallium ga-68 gozetotide in prostate cancer (PCa) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Disease localization by PSMA PET/MR at 2 years. Started Jun 2017; status: active, not recruiting.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03204123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03204123.